Patents by Inventor ANTHONY FRANCESCO PALERMO

ANTHONY FRANCESCO PALERMO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fused pyrimidine pyridinone compounds as JAK inhibitors
    Patent number: 11697648
    Abstract: The disclosure provides compounds of formula (I): or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The disclosure also provides pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat gastrointestinal inflammatory diseases.
    Type: Grant
    Filed: November 24, 2020
    Date of Patent: July 11, 2023
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Robert Murray McKinnell, Erik Fenster, Tom M. Lam, Diana Jin Wang, Anthony Francesco Palermo, Luke Boralsky, Breena Fraga
  • Imidazole and triazole containing bicyclic compounds as JAK inhibitors
    Patent number: 11339160
    Abstract: The invention provides compounds of formula (I): or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat gastrointestinal and other inflammatory diseases.
    Type: Grant
    Filed: October 23, 2020
    Date of Patent: May 24, 2022
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Robert Murray McKinnell, Erik Fenster, Tom M. Lam, Anthony Francesco Palermo
  • FUSED PYRIMIDINE PYRIDINONE COMPOUNDS AS JAK INHIBITORS
    Publication number: 20210188844
    Abstract: The disclosure provides compounds of formula (I): or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The disclosure also provides pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat gastrointestinal inflammatory diseases.
    Type: Application
    Filed: November 24, 2020
    Publication date: June 24, 2021
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Robert Murray McKinnell, Erik Fenster, Tom M. Lam, Diana Jin Wang, Anthony Francesco Palermo, Luke Boralsky, Breena Fraga
  • IMIDAZOLE AND TRIAZOLE CONTAINING BICYCLIC COMPOUNDS AS JAK INHIBITORS
    Publication number: 20210040085
    Abstract: The invention provides compounds of formula (I): or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat gastrointestinal and other inflammatory diseases.
    Type: Application
    Filed: October 23, 2020
    Publication date: February 11, 2021
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Robert Murray McKinnell, Erik Fenster, Tom M. Lam, Anthony Francesco Palermo
  • Imidazole and triazole containing bicyclic compounds as JAK inhibitors
    Patent number: 10851102
    Abstract: The invention provides compounds of formula (I): or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat gastrointestinal and other inflammatory diseases.
    Type: Grant
    Filed: January 22, 2020
    Date of Patent: December 1, 2020
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Robert Murray McKinnell, Erik Fenster, Tom M. Lam, Anthony Francesco Palermo
  • IMIDAZOLE AND TRIAZOLE CONTAINING BICYCLIC COMPOUNDS AS JAK INHIBITORS
    Publication number: 20200231590
    Abstract: The invention provides compounds of formula (I): or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat gastrointestinal and other inflammatory diseases.
    Type: Application
    Filed: January 22, 2020
    Publication date: July 23, 2020
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Robert Murray McKinnell, Erik Fenster, Tom M. Lam, Anthony Francesco Palermo
  • Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors
    Patent number: 10392368
    Abstract: The invention provides compounds of formula (I): or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The invention also provides crystalline forms, pharmaceutical compositions comprising such compounds, methods of using such compounds to treat gastrointestinal and other inflammatory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: August 27, 2019
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Erik Fenster, Tom M. Lam, Mandy Loo, Robert Murray McKinnell, Anthony Francesco Palermo, Diana Jin Wang, Breena Fraga, Jerry Nzerem, Marta Dabros, Venkat R. Thalladi, Miroslav Rapta
  • PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS
    Publication number: 20190040043
    Abstract: The invention provides compounds of formula (I): or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The invention also provides crystalline forms, pharmaceutical compositions comprising such compounds, methods of using such compounds to treat gastrointestinal and other inflammatory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: July 31, 2018
    Publication date: February 7, 2019
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: ERIK FENSTER, TOM M. LAM, MANDY LOO, ROBERT MURRAY MCKINNELL, ANTHONY FRANCESCO PALERMO, DIANA JIN WANG, BREENA FRAGA, JERRY NZEREM, MARTA DABROS, VENKAT R. THALLADI, MIROSLAV RAPTA